Rheumatology Unit, Rabin Medical Center - Beilinson Hospital, 4941492, Petach Tikva, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Arthritis Res Ther. 2019 Jan 7;21(1):10. doi: 10.1186/s13075-018-1779-5.
Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) is an innate-immune receptor found in blood. Its presence reflects innate immune cell activation. We sought to investigate plasma sTREM-1 levels in patients with primary antiphospholipid syndrome (PAPS).
A cross-sectional, case-control design was used. Plasma sTREM-1 levels were analyzed by enzyme-linked immunosorbent assay (ELISA) in consecutive patients diagnosed with PAPS or asymptomatic antiphospholipid antibody (APLA) carriers and controls.
The study cohort included 33 patients with PAPS, 10 asymptomatic APLA carriers, and 73 controls. Mean plasma sTREM-1 levels were significantly higher in patients with PAPS (299.2 ± 146.7 pg/ml) and thrombotic PAPS-ever (current and past thrombotic event) (327.2 ± 151.3 pg/ml) compared with controls (230.2 ± 85.5 pg/ml; p = 0.006 and p = 0.003, respectively), patients with thrombotic PAPS compared with patients with past obstetric APS (195.12 ± 58.52 pg/ml, p = 0.01) and APLA carriers (215.8 ± 51.6 pg/ml, p = 0.02), patients with current thrombotic PAPS (429.5 ± 227.5 pg/ml) compared with patients with past thrombotic PAPS (289.5 ± 94.65 pg/ml, p = 0.01), and patients with PAPS who had ever had a stroke or venous thromboembolic event compared with patients who had not (p = 0.007 and p = 0.02, respectively). On receiver operator characteristic curve analysis, plasma sTREM-1 levels differentiated patients with current thrombotic PAPS from asymptomatic APLA carriers and controls, with an area under the curve of 0.7292 (p = 0.0014) and 0.88 (p < 0.0001), respectively. Multivariate regression analysis to identify sTREM-1 predictors (thrombotic PAPS-ever, age, and sex) yielded an independent association of sTREM-1 levels with thrombotic PAPS (p < 0.0001).
Plasma sTREM-1 levels are significantly elevated in patients with thrombotic PAPS. Levels of sTREM-1 might serve as a biomarker for thrombosis in patients with PAPS.
可溶性髓系细胞触发受体-1（sTREM-1）是一种存在于血液中的先天免疫受体。它的存在反映了先天免疫细胞的激活。我们试图研究原发性抗磷脂综合征（PAPS）患者的血浆 sTREM-1 水平。
采用横断面、病例对照设计。通过酶联免疫吸附试验（ELISA）分析连续诊断为 PAPS 或无症状抗磷脂抗体（APLA）携带者和对照组患者的血浆 sTREM-1 水平。
研究队列包括 33 例 PAPS 患者、10 例无症状 APLA 携带者和 73 例对照。与对照组（230.2 ± 85.5 pg/ml；p = 0.006 和 p = 0.003）相比，PAPS 患者（299.2 ± 146.7 pg/ml）和血栓性 PAPS-既往（当前和既往血栓事件）患者（327.2 ± 151.3 pg/ml）的血浆 sTREM-1 水平显著升高，与对照组相比，血栓性 PAPS 患者（195.12 ± 58.52 pg/ml，p = 0.01）和 APLA 携带者（215.8 ± 51.6 pg/ml，p = 0.02）相比，当前血栓性 PAPS 患者（429.5 ± 227.5 pg/ml）与既往血栓性 PAPS 患者（289.5 ± 94.65 pg/ml，p = 0.01）相比，以及曾有过中风或静脉血栓栓塞事件的 PAPS 患者与未发生过此类事件的患者相比（p = 0.007 和 p = 0.02）。在接受者操作特征曲线分析中，血浆 sTREM-1 水平可区分当前血栓性 PAPS 患者与无症状 APLA 携带者和对照组，曲线下面积分别为 0.7292（p = 0.0014）和 0.88（p < 0.0001）。识别 sTREM-1 预测因子（血栓性 PAPS-既往、年龄和性别）的多元回归分析显示，sTREM-1 水平与血栓性 PAPS 独立相关（p < 0.0001）。
血栓性 PAPS 患者的血浆 sTREM-1 水平显著升高。sTREM-1 水平可能作为 PAPS 患者血栓形成的生物标志物。
